Ratiopharm, a pharmaceuticals company and major producer of generic drugs, has allegedly engaged in unethical marketing practices, including bribing doctors and pharmacists in Belgium, Canada, Spain, Estonia and Germany.
Relevant OECD Guidelines
In June 2006, the German NCP rejected the complaint citing the lack of transnational investment. Specifically, the NCP stated the complaint only dealt with alleged misbehaviour in Germany. In July 2006, Transparency International Germany resubmitted a revised and expanded complaint
- Gresea & Transparency International Germany vs Ratiopharm
- Transparency International Germany vs. Ratiopharm